Three Newly Recognized Likely Pathogenic Gene Variants Associated with Hereditary Transthyretin Amyloidosis
- PMID: 35933469
- PMCID: PMC9588125
- DOI: 10.1007/s40120-022-00385-1
Three Newly Recognized Likely Pathogenic Gene Variants Associated with Hereditary Transthyretin Amyloidosis
Abstract
Introduction: Hereditary transthyretin amyloidosis (ATTRv [variant]) is a clinically heterogeneous, progressively debilitating, fatal disease resulting from the deposition of insoluble amyloid fibrils in various organs and tissues. Early diagnosis of ATTRv can be facilitated with genetic testing; however, such testing of the TTR gene identifies variants of uncertain significance (VUS) in a minority of cases, a small percentage of which have the potential to be pathogenic. The Akcea/Ambry VUS Initiative is dedicated to gathering molecular, clinical, and inheritance data for each TTR VUS identified by genetic testing programs to reclassify TTR variants to a clinically actionable status (e.g., variant likely pathogenic [VLP]) where appropriate.
Methods: Classification criteria used here, based on recommendations from the American College of Medical Genetics and Genomics, are stringent and comprehensive, requiring distinct lines of evidence supporting pathogenesis.
Results: Three TTR variants have been reclassified from VUS to VLP, including c.194C>T (p.A65V), c.172G>C (p.D58H), and c.239C>T (p.T80I). In each case, the totality of genetic, structural, and clinical evidence provided strong support for pathogenicity.
Conclusions: Based on several lines of evidence, three TTR VUS were reclassified as VLP, resulting in a high likelihood of disease diagnosis for those and subsequent patients as well as at-risk family members.
Keywords: Hereditary transthyretin amyloidosis; Likely pathogenic variant; Reclassification, variant of uncertain significance; Variant of unknown significance.
© 2022. The Author(s).
Figures

Similar articles
-
Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.Neurol Ther. 2023 Feb;12(1):267-287. doi: 10.1007/s40120-022-00414-z. Epub 2022 Dec 16. Neurol Ther. 2023. PMID: 36525140 Free PMC article.
-
Management Targeted Genetic Evaluation of an Idiopathic Neuropathy Cohort Through ATTRv Amyloidosis Screening.HCA Healthc J Med. 2024 Aug 1;5(4):405-413. doi: 10.36518/2689-0216.1557. eCollection 2024. HCA Healthc J Med. 2024. PMID: 39290488 Free PMC article.
-
Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.Ann Med. 2021 Dec;53(1):1787-1796. doi: 10.1080/07853890.2021.1988696. Ann Med. 2021. PMID: 34658264 Free PMC article.
-
[A rare variant in the TTR gene (p.E112K) is associated with systemic amyloidosis and a new symptom - skin hyperemia in response to ethanol intake: family segregation analysis, literature review, and a clinical case. Case report].Ter Arkh. 2023 May 31;95(4):335-340. doi: 10.26442/00403660.2023.04.202160. Ter Arkh. 2023. PMID: 38158982 Review. Russian.
-
Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy.Drug Healthc Patient Saf. 2023 Feb 17;15:51-62. doi: 10.2147/DHPS.S338577. eCollection 2023. Drug Healthc Patient Saf. 2023. PMID: 36824481 Free PMC article. Review.
Cited by
-
Hereditary Transthyretin-Related Amyloidosis: Genetic Heterogeneity and Early Personalized Gene Therapy.Biomedicines. 2022 Sep 25;10(10):2394. doi: 10.3390/biomedicines10102394. Biomedicines. 2022. PMID: 36289657 Free PMC article. Review.
-
Unravelling the myriad physiologic roles of transthyretin: critical considerations for treating transthyretin amyloidosis.Ann Med. 2025 Dec;57(1):2536755. doi: 10.1080/07853890.2025.2536755. Epub 2025 Jul 27. Ann Med. 2025. PMID: 40717228 Free PMC article. Review.
-
Hereditary Transthyretin Amyloidosis in Patients Referred to a Genetic Testing Program.J Am Heart Assoc. 2024 Dec 3;13(23):e033770. doi: 10.1161/JAHA.123.033770. Epub 2024 Nov 22. J Am Heart Assoc. 2024. PMID: 39575713 Free PMC article.
-
A review of recent clinical trials to evaluate disease-modifying therapies in the treatment of cardiac amyloidosis.Front Med (Lausanne). 2024 Oct 30;11:1477988. doi: 10.3389/fmed.2024.1477988. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39540049 Free PMC article. Review.
References
-
- Sekijima Y. Hereditary transthyretin amyloidosis. Gene Reviews. Seattle: University of Washington; 2018. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous